These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 9219699)

  • 1. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
    N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
    Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
    Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.
    Mease PJ; Wei N; Fudman EJ; Kivitz AJ; Schechtman J; Trapp RG; Hobbs KF; Greenwald M; Hou A; Bookbinder SA; Graham GE; Wiesenhutter CW; Willis L; Ruderman EM; Forstot JZ; Maricic MJ; Dao KH; Pritchard CH; Fiske DN; Burch FX; Prupas HM; Anklesaria P; Heald AE
    J Rheumatol; 2010 Apr; 37(4):692-703. PubMed ID: 20032102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
    Lovell DJ; Giannini EH; Reiff A; Cawkwell GD; Silverman ED; Nocton JJ; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore J; Finck BK
    N Engl J Med; 2000 Mar; 342(11):763-9. PubMed ID: 10717011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.
    Murray KM; Dahl SL
    Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
    Moreland LW; Margolies G; Heck LW; Saway A; Blosch C; Hanna R; Koopman WJ
    J Rheumatol; 1996 Nov; 23(11):1849-55. PubMed ID: 8923355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticytokine therapy in rheumatoid arthritis.
    Firestein GS; Zvaifler NJ
    N Engl J Med; 1997 Jul; 337(3):195-7. PubMed ID: 9219708
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans.
    DeLa Cadena RA; Majluf-Cruz A; Stadnicki A; Tropea M; Reda D; Agosti JM; Colman RW; Suffredini AF
    Thromb Haemost; 1998 Jul; 80(1):114-8. PubMed ID: 9684796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
    Tugwell P; Pincus T; Yocum D; Stein M; Gluck O; Kraag G; McKendry R; Tesser J; Baker P; Wells G
    N Engl J Med; 1995 Jul; 333(3):137-41. PubMed ID: 7791814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation and radiological observation of recombinant human tumor necrosis factor receptor-Fc fusion protein in treatment of active ankylosing spondylitis].
    Pan XY; Li J; Pang J; Dai SH; Chen WG
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1408-11. PubMed ID: 18953881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
    Furst DE; Fleischmann R; Kopp E; Schiff M; Edwards C; Solinger A; Macri M;
    J Rheumatol; 2005 Dec; 32(12):2303-10. PubMed ID: 16331754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.